Treatment options for hepatobiliary and pancreatic cancer.
Hepatobiliary and pancreatic cancers account for 4% of all cancers in the United States. Traditionally, these cancers have had a high mortality rate and have been poorly responsive to therapy. Because of a growing number of treatment options, patients are now living longer. For hepatocellular carcinoma, a broad number of treatment options are available, including surgery, ablation, embolization, systemic therapy, and liver transplantation. Treatment options for cholangiocarcinoma include surgery, systemic therapy, and liver transplantation. For pancreatic cancer, surgery, radiation, and systemic therapy all have potential roles. This review provides an updated summary of diagnosis and assessment together with treatment options for this group of cancers.
Alberts
Steven R
SR
Division of Medical Oncology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA. alberts.steven@mayo.edu
Gores
Gregory J
GJ
Kim
George P
GP
Roberts
Lewis R
LR
Kendrick
Michael L
ML
Rosen
Charles B
CB
Chari
Suresh T
ST
Martenson
James A
JA
D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic; D006528:Carcinoma, Hepatocellular / Q000601:surgery; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000601:surgery*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000431:Ethanol / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery*; D016031:Liver Transplantation; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016019:Survival Analysis; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000431:Ethanol; D000093542:Gemcitabine